Table 4 Multivariate analysis of prognostic factors
Variate | OS | PFS | DMFS | LRRFS | ||||
|---|---|---|---|---|---|---|---|---|
RR(95% CI) | P | RR(95% CI) | P | RR(95% CI) | P | RR(95% CI) | P | |
Group | ||||||||
RV-IMRT vs. CV-IMRT | 0.580 (0.257–1.309) | 0.19 | 0.826 (0.420–1.622) | 0.578 | 1.285 (0.538–3.070) | 0.573 | 0.553 (0.203–1.502) | 0.245 |
Gender | ||||||||
 Male vs. Female | 0.970 (0.382–2.464) | 0.95 | 1.918 (0.736–4.998) | 0.183 | 2.979 (0.684–12.978) | 0.146 | 1.563 (0.439–5.562) | 0.49 |
Age | ||||||||
  ≥ 45 vs. < 45 | 2.408 (1.037–5.595) | 0.041 | 1.451 (0.724–2.908) | 0.294 | 1.053 (0.438–2.528) | 0.909 | 1.607 (0.575–4.490) | 0.365 |
T stage | ||||||||
 T3–4 vs. T1–2 | 0.817 (0.340–1.964) | 0.651 | 0.916 (0.415–2.021) | 0.828 | 1.068 (0.396–2.885) | 0.896 | 1.179 (0.368–3.776) | 0.781 |
N stage | ||||||||
 N2–3 vs. N0–1 | 2.455 (0.649–9.279) | 0.186 | 2.192 (0.687–6.992) | 0.185 | 2.715 (0.556–13.257) | 0.217 | 1.490 (0.361–6.159) | 0.581 |
Clinical stage | ||||||||
 III-IV vs. I-II | 3.280 (0.281–38.226) | 0.343 | 0.926 (0.183–4.683) | 0.926 | 0.730 (0.080–6.639) | 0.78 | 1.165 (0.129–10.480) | 0.892 |
Neoadjuvant/adjuvant chemotherapy | ||||||||
 Yes vs. No | 0.600 (0.085–4.238) | 0.608 | 0.695 (0.108–4.464) | 0.702 | 1.764 (0.084–36.960) | 0.715 | 0.404 (0.047–3.457) | 0.408 |
Concurrent chemotherapy | ||||||||
 Yes vs. No | 0.987 (0.041–23.701) | 0.994 | 3.338 (0.237–46.915) | 0.371 | 0.796 (0.030–20.935) | 0.891 | – | – |